



The 12th Biennial Ovarian Cancer Research Symposium is presented by the Rivkin Center for Ovarian Cancer and the American Association for Cancer Research. The goal of the Symposium is to bring together clinicians and researchers from across many disciplines and institutions worldwide in order to encourage collaborations toward advancing the field of ovarian cancer research. The conference seeks to enhance the understanding and knowledge of ovarian cancer, especially among junior investigators, discuss the most recent innovations in the field of ovarian cancer research, and address pressing concerns of the leaders in the clinical and research community.

Agenda

Day 1: September 13, 2018	
3:00 PM	Registration and Poster Set-up
4:00 PM – 4:15 PM	Welcome
4:15 PM – 5:30 PM	EDUCATION SESSION: CURRENT CHALLENGES IN OVARIAN CANCER <i>Biology of Ovarian Cancer</i> Douglas Levine, MD (NYU Langone) <i>Tumor Microenvironment and Immunology of Ovarian Cancer</i> Brad Nelson, PhD (British Columbia Cancer Agency) <i>Clinical Management of Ovarian Cancer</i> Elizabeth Swisher, MD (University of Washington)
5:30 PM – 6:30 PM	KEYNOTE ADDRESS <i>Title TBA</i> Mary-Claire King, PhD (University of Washington)
6:30 PM – 8:30 PM	Welcome Reception and Poster Session I
Day 2: September 14, 2018	
7:30 AM – 8:30 AM	Breakfast and Registration
8:30 AM – 12:00 PM	SESSION I: DETECTION AND PREVENTION Chair: Elizabeth Swisher, MD (University of Washington) INVITED SPEAKERS <i>Population testing for ovarian cancer gene mutations for primary prevention</i> Ranjit Manchanda, MD/PhD (Barts Cancer Institute) <i>Ovarian cancer detection using ultra-sensitive sequencing: challenges and opportunities</i> Rosana Risques, PhD (University of Washington)

	<p>ABSTRACT PRESENTATIONS</p> <p><i>Lineage continuity between early tubal serous proliferations (ESPs/STILs) and disseminated high-grade serous carcinomas: a model for “precursor escape”</i> Thing Rinda Soong, MD/PhD (University of Washington)</p> <p><i>Exposing the local factors that contribute to ovarian colonization of fallopian tube-derived tumors</i> Joanna Burdette, PhD (University of Illinois, Chicago)</p> <p><i>Distinct Cell/Tissue Sources of High-grade Serous Ovarian Cancer</i> Shuang Zhang, PhD (NYU School of Medicine)</p> <p><i>Increasing Access to Genetic Testing for Hereditary Breast and Ovarian Cancer: Experience from High-Volume OB/GYN clinic in Texas</i> Carmelina Heydrich, MS GC (Color Genomics)</p> <p><i>Ovarian cancer-associated RAD51D mutations which impair its interaction with XRCC2 result in DNA repair deficiency</i> Kara Bernstein, PhD (University of Pittsburgh)</p> <p><i>Metabolic syndrome and risk of ovarian cancer in the United States: an analysis of linked SEER–Medicare data</i> Kara Michels, PhD (National Cancer Institute)</p> <p><i>Protein and Imaging Markers for Early Detection of Epithelial Ovarian Cancer</i> Jennifer Barton, PhD (University of Arizona)</p> <p><i>Development of a Multi-Protein Classifier for Ovarian Cancer Detection by Simultaneous Measurement of 92 Serum Proteins on Proseek Multiplex Oncology II Plates</i> Amy Skubitz, PhD (University of Minnesota)</p>
12:05 PM – 1:30 PM	Lunch
12:30 PM – 1:30 PM	<p>MEET THE EXPERTS ROUNDTABLE</p> <p><i>State of Early Detection of Ovarian Cancer</i> Charles Drescher, MD (Swedish Cancer Institute) Yang Yang Hartwich, PhD (Yale University)</p> <p><i>Role of the Microenvironment in Ovarian Cancer Progression</i> Pamela Ohashi, PhD (Princess Margaret Cancer Centre) Anirban Mitra, PhD (Indiana University School of Medicine)</p> <p><i>Immunotherapy</i> Mary (Nora) L. Disis, MD (University of Washington) Juan Ruiz, PhD (Weill Cornell Medical College)</p> <p><i>Future of Ovarian Cancer Therapies</i> Ursula Matulonis, MD (Dana-Farber Cancer Institute) Wa Xian, PhD (University of Texas, Houston)</p>

	<p><i>PARP Inhibitors and Resistance Mechanisms</i> Alan D’Andrea, MD (Dana-Farber Cancer Institute) Neil Johnson, PhD (Fox Chase Cancer Center)</p> <p><i>Genetic Testing: Implications for Prevention and Treatment</i> Elizabeth Swisher, MD (University of Washington) Ranjit Manchanda, MD/PhD (Barts Cancer Institute)</p> <p><i>Communicating Science to the General Public</i> Frances Balkwill, PhD (Barts Cancer Institute) Dmitriy Zamarin, MD/PhD (Memorial Sloan Kettering Cancer Center)</p>
<p>1:30 PM – 5:30 PM</p>	<p>SESSION II: GENOMICS AND MOLECULAR MECHANISMS Chair: Pamela Ohashi, PhD (Princess Margaret Cancer Centre)</p> <p>INVITED SPEAKERS</p> <p><i>Targeting DNA Repair in Ovarian Cancer</i> Alan D’Andrea, MD (Dana Farber Cancer Institute)</p> <p><i>Modeling the Genomics of High-Grade Serous Carcinoma in the Mouse</i> Kathleen Cho, MD (University of Michigan)</p> <p>ABSTRACT PRESENTATIONS</p> <p><i>Copy-number signatures and mutational processes in high grade serous ovarian carcinoma</i> James Brenton, MD/PhD (University of Cambridge)</p> <p><i>Real-time assessment of HGSC DNA damage repair defects and defect-induced response to therapy in ovarian cancer organoids</i> Sarah Hill, MD/PhD (Dana-Farber Cancer Institute)</p> <p><i>Identifying functional noncoding somatic mutations in ovarian cancer</i> Rosario Corona, PhD (Cedars-Sinai Medical Center)</p> <p><i>FOXM1 induces DNA replication stress and promotes genomic instability downstream of Cyclin E1 in high-grade serous ovarian cancer</i> Carter Barger, PhD (University of Nebraska Medical Center)</p> <p><i>Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity</i> Jeremy Chien, PhD (University of New Mexico)</p> <p><i>Pooled genomic screens identify anti-apoptotic genes as mediators of chemotherapy resistance in ovarian cancer</i> Elizabeth Stover, MD/PhD (Dana-Farber Cancer Institute)</p>

	<p><i>Identification of P53 Prions as an Independent Prognostic Marker for Survival in High-Grade Serous Ovarian Cancer</i> Nicole Heinzl, MSc (Medical University of Vienna)</p> <p><i>Modeling Endometrioid and High Grade Serous Carcinomas in the Mouse Using CRISPR/Cas9-Mediated Somatic Gene Editing in Fallopian Tube Epithelium</i> Rong Wu, MD (University of Michigan Medical School)</p>
5:15 PM – 6:30 PM	<p>PANEL: THE ROLE OF ADVOCATES IN OVARIAN CANCER RESEARCH Nita Maihle, PhD (Augusta University) Marcie Paul (Advocate) Jaime Crase (Advocate) Celeste Leigh Pearce, PhD, MPH (University of Michigan) Moderators: Erinn Rankin, PhD (Stanford University) and Dmitriy Zamarin, MD/PhD (Memorial Sloan Kettering Cancer Center)</p>
6:30 PM – 8:30 PM	<p>Reception and Poster Session II</p>

Day 3: September 15, 2018	
7:30 AM – 8:30 AM	Breakfast and Registration
8:30 AM – 12:00 PM	<p>SESSION III: TUMOR MICROENVIRONMENT AND IMMUNOLOGY Chair: Frances Balkwill, PhD (Barts Cancer Institute)</p> <p>INVITED SPEAKERS</p> <p><i>Deconstructing and reconstructing the microenvironment of high-grade serous ovarian cancer</i> Frances Balkwill, PhD (Barts Cancer Institute)</p> <p><i>Multi-level proteomics identifies cancer testis antigens as mediator of chemosensitivity and immunotherapy target in ovarian cancer</i> Ernst Lengyel, MD/PhD (University of Chicago)</p> <p>ABSTRACT PRESENTATIONS</p> <p><i>Molecular and functional heterogeneity of cancer associated fibroblasts in high-grade serous ovarian cancer</i> Laurie Ailles, PhD (University Health Network)</p> <p><i>Pro-invasive tumour-stroma interactions: role of the secreted oxidoreductase CLIC3</i> Sara Zanivan, PhD (Cancer Research UK Beatson Institute)</p> <p><i>Collagen alterations in human ovarian cancer probed by Second Harmonic Generation (SHG) imaging microscopy</i> Paul Campagnola, PhD (University of Wisconsin-Madison)</p> <p><i>Stromal cell expression of the receptor tyrosine kinase DDR2 promotes ovarian cancer metastasis</i> Katherine Fuh, MD/PhD (Washington University)</p>

	<p><i>A novel target for overcoming adaptive resistance to anti-angiogenic therapy in ovarian cancer</i> Yunfei Wen, PhD (The University of Texas, MD Anderson Cancer Center)</p> <p><i>DNA damage responses and immune profiling through highly multiplexed tissue immunofluorescence (t-CyCIF) in high-grade serous ovarian cancer</i> Anniina Farkkila, MD/PhD (Dana-Farber Cancer Institute)</p> <p><i>Early loss of monoubiquitylation of Histone H2B alters key immune signaling pathways promoting the progression of high-grade serous ovarian cancer</i> Jagmohan Hooda, PhD (University of Pennsylvania)</p> <p><i>Alternatively Activated Macrophage Secretome Modulates Metastatic Potential of Ovarian Cancer Cells</i> Kaitlin Fogg, PhD (University of Wisconsin – Madison)</p>
<p>12:05 PM – 1:30 PM</p>	<p>Lunch</p>
<p>12:10 PM – 1:15 PM</p>	<p>Summit: Measuring the Success and Impact of Ovarian Cancer Nonprofit Research Funding Powel Crosely (Granulosa Cell Tumour Research Foundation) Kiran Dhillon, PhD (Rivkin Center for Ovarian Cancer) Susan Leighton (Ovarian Cancer Research Funding Alliance) Adoracion Pegalajar-Jurado (OvaCure) (HUB 214; Limited Seating)</p>
<p>1:30 PM – 5:30 PM</p>	<p>SESSION IV: NOVEL THERAPEUTICS: RESPONSE AND RESISTANCE Chair: Nora Disis, MD (University of Washington)</p> <p>INVITED SPEAKERS</p> <p><i>Novel Combination Strategies for Recurrent Ovarian Cancer</i> Ursula Matulonis, MD (Dana-Farber Cancer Institute)</p> <p><i>Cell Cycle Checkpoints as Therapeutic Targets</i> Jung-Min Lee, MD (National Cancer Institute)</p> <p>ABSTRACT PRESENTATIONS</p> <p><i>Total Abdominal Ultra-Rapid FLASH Irradiation Demonstrates Decreased Gastrointestinal Toxicity Compared to Conventional Total Abdominal Irradiation in Mice</i> Karen Levy, MD (Stanford University)</p> <p><i>Cancer Stem Cells: Distinct Seeds for Recurrent Ovarian Cancer</i> Nuzhat Ahmed, PhD (Fiona Elsey Cancer Research Institute, Ballarat, Australia)</p> <p><i>A phase 2 study of TPIV200/huFR-1 (a multi-epitope folate receptor alpha vaccine) in combination with durvalumab in patients with platinum resistant ovarian cancer</i> Dmitriy Zamarin, MD/PhD (Memorial Sloan Kettering Cancer Center)</p>

	<p><i>Antitumor response after vaccination targeting insulin growth factor binding protein 2 in a syngeneic mouse model of ovarian cancer localized by three-dimensional in vivo optical imaging</i> Denise Cecil, MD/PhD (University of Washington)</p> <p><i>A single cell RNA-sequencing approach to uncovering human ovarian tumor and immune cell heterogeneity, and their response to Mullerian Inhibiting Substance using patient ascites samples</i> David Pepin, PhD (Massachusetts General Hospital, Harvard Medical School)</p> <p><i>BRCA1 intron retention generates truncated proteins that avoid BRCT mutation misfolding and promote PARP inhibitor resistance</i> Neil Johnson, PhD (Fox Chase Cancer Center)</p> <p><i>ATR inhibition targets treatment resistant ovarian cancer</i> Erin George, MD (University of Pennsylvania)</p> <p><i>The role of NFAT3 in Ovarian Cancer Quiescence and Chemotherapy Resistance</i> Alex Cole, PhD (University of Michigan)</p>
5:30 PM	Closing Remarks & Departure

Planning Committee Members

Frances Balkwill, PhD (Co-Chair) <i>Barts Cancer Institute</i>	Mary L. (Nora) Disis, MD (Co-Chair) <i>University of Washington</i>	Elizabeth Swisher, MD (Co-Chair) <i>University of Washington</i>	Pamela Ohashi, PhD (Co-Chair) <i>Princess Margaret Cancer Center</i>
Amy Baran, PhD <i>American Association for Cancer Research</i>	Kiran Dhillon, PhD <i>Rivkin Center</i>	Saul Rivkin, MD <i>Rivkin Center</i>	